You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Drug Price Trends for CARBIDOPA-LEVODOPA-ENTACAPONE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for CARBIDOPA-LEVODOPA-ENTACAPONE

Average Pharmacy Cost for CARBIDOPA-LEVODOPA-ENTACAPONE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
CARBIDOPA-LEVODOPA-ENTACAPONE 18.75-75-200 MG TAB 16571-0690-01 0.81816 EACH 2025-01-22
CARBIDOPA-LEVODOPA-ENTACAPONE 12.5-50-200 MG TAB 00781-5613-01 0.97631 EACH 2025-01-22
CARBIDOPA-LEVODOPA-ENTACAPONE 25-100-200 MG TAB 00781-5637-01 0.73081 EACH 2025-01-22
CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB 16571-0694-01 0.72683 EACH 2025-01-22
CARBIDOPA-LEVODOPA-ENTACAPONE 12.5-50-200 MG TAB 16571-0689-01 0.97631 EACH 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Carbidopa-Levodopa-Entacapone

Introduction to Carbidopa-Levodopa-Entacapone

Carbidopa-levodopa-entacapone is a combination medication used primarily in the treatment of Parkinson's disease. This drug combines carbidopa, levodopa, and entacapone to manage the symptoms of Parkinson's, particularly the "off" periods where the effectiveness of levodopa diminishes.

Market Growth and Drivers

The global market for carbidopa-levodopa-entacapone is anticipated to grow significantly, driven by several key factors:

Increasing Prevalence of Parkinson's Disease

The prevalence of Parkinson's disease is on the rise, with approximately 10 million people worldwide living with the condition. In the United States alone, nearly one million people are affected, and this number is expected to increase to 1.2 million by 2030[1][3].

Advancements in Drug Formulations

Recent advancements in drug formulations, such as extended-release versions, are enhancing the efficacy and patient compliance of carbidopa-levodopa-entacapone. These innovations improve the therapeutic outcomes by ensuring consistent treatment without the need for frequent dosing[3].

Heightened Awareness and Regulatory Support

Increased awareness among healthcare providers and patients about the treatment options for Parkinson's disease is driving demand. Regulatory agencies are also becoming more supportive, facilitating quicker approvals for new formulations and encouraging investment in research and development[3].

Market Size and Projections

The global entacapone market, which includes carbidopa-levodopa-entacapone combinations, is projected to grow at a compound annual growth rate (CAGR) of around 5-7% over the next five years. This growth is largely attributed to the increasing prevalence of Parkinson's disease and the aging population globally[1][3].

Price Analysis

The cost of carbidopa-levodopa-entacapone can vary based on the dosage and the pharmacy. Here are some approximate price ranges for different formulations:

  • 12.5 mg-200 mg-50 mg oral tablet: Around $328 for a supply of 100 tablets[2].
  • 18.75 mg-200 mg-75 mg oral tablet: Starting from $328.32 for 100 tablets[2].
  • 31.25 mg-200 mg-125 mg oral tablet: Starting from $169.45 for 100 tablets[2].
  • 37.5 mg-200 mg-150 mg oral tablet: Starting from $328.32 for 100 tablets[2].
  • 50 mg-200 mg-200 mg oral tablet: Starting from $129.49 for 100 tablets[2].

These prices are for cash-paying customers and may vary depending on insurance plans and pharmacy discounts.

Competitive Landscape

The market for carbidopa-levodopa-entacapone is competitive, with several major pharmaceutical companies playing key roles:

  • Novartis International AG: Known for its brand names such as Stalevo 50, Stalevo 100, Stalevo 200, and Stalevo 75[2].
  • Teva Pharmaceutical Industries Ltd.: Active in the market through various product offerings and strategic partnerships[1].
  • Sun Pharmaceutical Industries Ltd.: Also a significant player, contributing to market growth through new product launches and collaborations[1].

These companies are adopting strategies such as mergers and acquisitions, geographical expansion, partnerships, and new product launches to maintain their competitive edge[1].

Regional Market Analysis

The global market for carbidopa-levodopa-entacapone is segmented into several regions:

  • North America: Includes the United States and Canada, with a significant market share due to high awareness and advanced healthcare systems[1].
  • Europe: Countries like the UK, Germany, Italy, Spain, and France are key markets, driven by a high prevalence of Parkinson's disease and supportive regulatory environments[1].
  • Asia-Pacific: Countries such as China, India, Japan, and South Korea are experiencing rapid growth due to an increasing aging population and improving healthcare infrastructure[1].
  • Rest of the World: Includes Latin America and the Middle East & Africa, which are also seeing growth driven by increasing awareness and improving healthcare access[1].

Impact of COVID-19

The COVID-19 pandemic has had a mixed impact on the market. While it caused initial disruptions in supply chains and healthcare services, it also highlighted the need for effective treatments for chronic diseases like Parkinson's. Regulatory agencies have been supportive, facilitating quicker approvals for new formulations to address the ongoing demand[5].

Strategic Partnerships and Innovations

Strategic partnerships between pharmaceutical companies and research institutions are crucial for the growth of the carbidopa-levodopa-entacapone market. These collaborations focus on optimizing existing formulations and exploring new therapeutic applications. For instance, studies are ongoing to investigate the potential of entacapone in treating other neurological disorders, which could expand its market reach[3].

Public Awareness and Educational Campaigns

Public and professional awareness of Parkinson's disease and its treatment options is vital for driving demand for carbidopa-levodopa-entacapone. Educational campaigns targeting both healthcare providers and patients can significantly influence prescribing practices and treatment adherence. These initiatives emphasize the importance of early diagnosis and effective management, leading to better patient outcomes[3].

Key Takeaways

  • The global market for carbidopa-levodopa-entacapone is expected to grow significantly due to the increasing prevalence of Parkinson's disease and advancements in drug formulations.
  • The market is driven by major pharmaceutical companies through strategic partnerships, new product launches, and geographical expansions.
  • The cost of the medication varies based on dosage and pharmacy, with prices ranging from approximately $129 to $328 for a supply of 100 tablets.
  • Regulatory support and public awareness campaigns are crucial for market growth.
  • The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World, with each region showing promising growth potential.

FAQs

What is the primary use of carbidopa-levodopa-entacapone?

Carbidopa-levodopa-entacapone is primarily used to treat Parkinson's disease, particularly to manage the "off" periods where the effectiveness of levodopa diminishes.

How is the market for carbidopa-levodopa-entacapone expected to grow?

The market is expected to grow at a CAGR of around 5-7% over the next five years, driven by the increasing prevalence of Parkinson's disease and advancements in drug formulations.

What are the key factors driving the growth of the carbidopa-levodopa-entacapone market?

Key factors include the increasing prevalence of Parkinson's disease, advancements in drug formulations, heightened awareness of treatment options, and supportive regulatory environments.

Which regions are significant in the carbidopa-levodopa-entacapone market?

North America, Europe, Asia-Pacific, and the Rest of the World are significant regions, with North America and Europe being the most prominent due to high awareness and advanced healthcare systems.

How has COVID-19 impacted the carbidopa-levodopa-entacapone market?

COVID-19 caused initial disruptions but also highlighted the need for effective treatments for chronic diseases. Regulatory agencies have been supportive, facilitating quicker approvals for new formulations.

Sources

  1. OMR Global: Global Entacapone Market Size, Share and Trends Analysis Report.
  2. Drugs.com: Carbidopa/entacapone/levodopa Prices, Coupons, Copay Cards & Patient Assistance.
  3. Market Research Intellect: Entacapone Market Growth: A New Chapter in Parkinson's Disease Management.
  4. Allied Market Research: Levodopa Market Size, Growth Analysis | Forecast - 2032.
  5. GlobeNewswire: Entacapone Market 2022 to Showing Impressive Growth by.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.